TG Therapeutics Plans Cut-Price Challenger To Ocrevus In MS

Filing Expected In Q3

 
• By Andrew McConaghie

TG Therapeutics is confident its late-stage candidate can take a slice of the multiple sclerosis market away from Roche’s blockbuster.

Brain with MS
An MRI of the brain of an MS patient, yellow-gold-orange showing areas of demyelination. • Source: Alamy

More from Anticancer

More from Therapy Areas